Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis
We studied the relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation. Change in bone turnove...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2001-11, Vol.12 (11), p.922-930 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 930 |
|---|---|
| container_issue | 11 |
| container_start_page | 922 |
| container_title | Osteoporosis international |
| container_volume | 12 |
| creator | BJARNASON, N. H SARKAR, S DUONG, T MITLAK, B DELMAS, P. D CHRISTIANSEN, C |
| description | We studied the relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation. Change in bone turnover was significantly related to future risk of vertebral fracture, also after adjusting for baseline vertebral fracture status and BMD. Thus, for a decrease of 9.3 pg/l in serum osteocalcin after 1 year's raloxifene therapy, the odds ratio (OR) for a new vertebral fracture during 3 years was 0.69 (0.54-0.88), p = 0.003. Similarly, for a decrease of 5.91 microg/l in serum bone alkaline phosphatase, OR was 0.75 (0.62-0.92), p = 0.005. The change in BMD over 12 and 24 months was not related to fracture risk in any of the analyses. The strongest predictor for vertebral fracture was prevalent vertebral fracture--even during therapy. The predictive value of baseline BMD was in the same order of magnitude as bone turnover change during raloxifene treatment. In conclusion, the change in bone turnover is related to fracture risk during raloxifene therapy. In contrast the change in BMD is not related to fracture risk. The strongest predictor for vertebral fracture is prevalent vertebral fracture. |
| doi_str_mv | 10.1007/s001980170020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954612333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18404856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-d702843436d33b8a5fd5d126c903e17b6698e8ce1ff27e4bbe1e7b3563edc663</originalsourceid><addsrcrecordid>eNqF0k1vFSEUBmBiNPb26tKtISbW1SgMn7NsGr-SJi7swt2EgTMtdQZGYGr7i_ybMulNGl0oGyA8vAQ4CL2g5C0lRL3LhNBOE6oIackjtKOcsabtpHiMdqRjquk4_XaEjnO-JtV3nXqKjijVRAvOd-jXV3-LTXC4_ITpBvAcQ7nC9sqES8jYBzzEALisKcQbSNgkwAkmU6DuiHXoVlt8DJus6wWGZCY8JmPrlkp9_o7dmny4xAzfgUkZxxFXE2_9CFtyAlNmCGVLWGLexnExa64xdQZxiSlmn5-hJ6OZMjw_9Ht08eH9xdmn5vzLx89np-eN5UqUxinSas44k46xQRsxOuFoK21HGFA1SNlp0BboOLYK-DAABTUwIRk4KyXbozf3sUuKP1bIpZ99tjBNJkBcc98JLmnLatujk39K1XJKts_4H6SaE67Fdvarv-B1rO9eb9vrCpTQUlTU3CNbnyUnGPsl-dmku56SfiuI_o-CqP7lIXQdZnAP-lABFbw-AJOtmerXBevzg-OUtrQW0m-jpsBG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>848575865</pqid></control><display><type>article</type><title>Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>BJARNASON, N. H ; SARKAR, S ; DUONG, T ; MITLAK, B ; DELMAS, P. D ; CHRISTIANSEN, C</creator><creatorcontrib>BJARNASON, N. H ; SARKAR, S ; DUONG, T ; MITLAK, B ; DELMAS, P. D ; CHRISTIANSEN, C</creatorcontrib><description>We studied the relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation. Change in bone turnover was significantly related to future risk of vertebral fracture, also after adjusting for baseline vertebral fracture status and BMD. Thus, for a decrease of 9.3 pg/l in serum osteocalcin after 1 year's raloxifene therapy, the odds ratio (OR) for a new vertebral fracture during 3 years was 0.69 (0.54-0.88), p = 0.003. Similarly, for a decrease of 5.91 microg/l in serum bone alkaline phosphatase, OR was 0.75 (0.62-0.92), p = 0.005. The change in BMD over 12 and 24 months was not related to fracture risk in any of the analyses. The strongest predictor for vertebral fracture was prevalent vertebral fracture--even during therapy. The predictive value of baseline BMD was in the same order of magnitude as bone turnover change during raloxifene treatment. In conclusion, the change in bone turnover is related to fracture risk during raloxifene therapy. In contrast the change in BMD is not related to fracture risk. The strongest predictor for vertebral fracture is prevalent vertebral fracture.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s001980170020</identifier><identifier>PMID: 11808544</identifier><language>eng</language><publisher>London: Springer</publisher><subject>Alkaline Phosphatase - metabolism ; Biological and medical sciences ; Biomarkers ; Bone Remodeling - drug effects ; Bone Remodeling - physiology ; Bones, joints and connective tissue. Antiinflammatory agents ; Chi-Square Distribution ; Collagen - metabolism ; Enzyme-Linked Immunosorbent Assay ; Estrogen Antagonists - therapeutic use ; Female ; Humans ; Logistic Models ; Medical sciences ; Multivariate Analysis ; Osteocalcin - metabolism ; Osteoporosis, Postmenopausal - complications ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporosis, Postmenopausal - metabolism ; Pharmacology. Drug treatments ; Raloxifene Hydrochloride - therapeutic use ; Risk Factors ; Spinal Fractures - etiology ; Spinal Fractures - prevention & control</subject><ispartof>Osteoporosis international, 2001-11, Vol.12 (11), p.922-930</ispartof><rights>2002 INIST-CNRS</rights><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-d702843436d33b8a5fd5d126c903e17b6698e8ce1ff27e4bbe1e7b3563edc663</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14112109$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11808544$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BJARNASON, N. H</creatorcontrib><creatorcontrib>SARKAR, S</creatorcontrib><creatorcontrib>DUONG, T</creatorcontrib><creatorcontrib>MITLAK, B</creatorcontrib><creatorcontrib>DELMAS, P. D</creatorcontrib><creatorcontrib>CHRISTIANSEN, C</creatorcontrib><title>Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><description>We studied the relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation. Change in bone turnover was significantly related to future risk of vertebral fracture, also after adjusting for baseline vertebral fracture status and BMD. Thus, for a decrease of 9.3 pg/l in serum osteocalcin after 1 year's raloxifene therapy, the odds ratio (OR) for a new vertebral fracture during 3 years was 0.69 (0.54-0.88), p = 0.003. Similarly, for a decrease of 5.91 microg/l in serum bone alkaline phosphatase, OR was 0.75 (0.62-0.92), p = 0.005. The change in BMD over 12 and 24 months was not related to fracture risk in any of the analyses. The strongest predictor for vertebral fracture was prevalent vertebral fracture--even during therapy. The predictive value of baseline BMD was in the same order of magnitude as bone turnover change during raloxifene treatment. In conclusion, the change in bone turnover is related to fracture risk during raloxifene therapy. In contrast the change in BMD is not related to fracture risk. The strongest predictor for vertebral fracture is prevalent vertebral fracture.</description><subject>Alkaline Phosphatase - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Bone Remodeling - drug effects</subject><subject>Bone Remodeling - physiology</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Chi-Square Distribution</subject><subject>Collagen - metabolism</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Estrogen Antagonists - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Medical sciences</subject><subject>Multivariate Analysis</subject><subject>Osteocalcin - metabolism</subject><subject>Osteoporosis, Postmenopausal - complications</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Osteoporosis, Postmenopausal - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Raloxifene Hydrochloride - therapeutic use</subject><subject>Risk Factors</subject><subject>Spinal Fractures - etiology</subject><subject>Spinal Fractures - prevention & control</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqF0k1vFSEUBmBiNPb26tKtISbW1SgMn7NsGr-SJi7swt2EgTMtdQZGYGr7i_ybMulNGl0oGyA8vAQ4CL2g5C0lRL3LhNBOE6oIackjtKOcsabtpHiMdqRjquk4_XaEjnO-JtV3nXqKjijVRAvOd-jXV3-LTXC4_ITpBvAcQ7nC9sqES8jYBzzEALisKcQbSNgkwAkmU6DuiHXoVlt8DJus6wWGZCY8JmPrlkp9_o7dmny4xAzfgUkZxxFXE2_9CFtyAlNmCGVLWGLexnExa64xdQZxiSlmn5-hJ6OZMjw_9Ht08eH9xdmn5vzLx89np-eN5UqUxinSas44k46xQRsxOuFoK21HGFA1SNlp0BboOLYK-DAABTUwIRk4KyXbozf3sUuKP1bIpZ99tjBNJkBcc98JLmnLatujk39K1XJKts_4H6SaE67Fdvarv-B1rO9eb9vrCpTQUlTU3CNbnyUnGPsl-dmku56SfiuI_o-CqP7lIXQdZnAP-lABFbw-AJOtmerXBevzg-OUtrQW0m-jpsBG</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>BJARNASON, N. H</creator><creator>SARKAR, S</creator><creator>DUONG, T</creator><creator>MITLAK, B</creator><creator>DELMAS, P. D</creator><creator>CHRISTIANSEN, C</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis</title><author>BJARNASON, N. H ; SARKAR, S ; DUONG, T ; MITLAK, B ; DELMAS, P. D ; CHRISTIANSEN, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-d702843436d33b8a5fd5d126c903e17b6698e8ce1ff27e4bbe1e7b3563edc663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Alkaline Phosphatase - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Bone Remodeling - drug effects</topic><topic>Bone Remodeling - physiology</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Chi-Square Distribution</topic><topic>Collagen - metabolism</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Estrogen Antagonists - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Medical sciences</topic><topic>Multivariate Analysis</topic><topic>Osteocalcin - metabolism</topic><topic>Osteoporosis, Postmenopausal - complications</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Osteoporosis, Postmenopausal - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Raloxifene Hydrochloride - therapeutic use</topic><topic>Risk Factors</topic><topic>Spinal Fractures - etiology</topic><topic>Spinal Fractures - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BJARNASON, N. H</creatorcontrib><creatorcontrib>SARKAR, S</creatorcontrib><creatorcontrib>DUONG, T</creatorcontrib><creatorcontrib>MITLAK, B</creatorcontrib><creatorcontrib>DELMAS, P. D</creatorcontrib><creatorcontrib>CHRISTIANSEN, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BJARNASON, N. H</au><au>SARKAR, S</au><au>DUONG, T</au><au>MITLAK, B</au><au>DELMAS, P. D</au><au>CHRISTIANSEN, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis</atitle><jtitle>Osteoporosis international</jtitle><addtitle>Osteoporos Int</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>12</volume><issue>11</issue><spage>922</spage><epage>930</epage><pages>922-930</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>We studied the relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation. Change in bone turnover was significantly related to future risk of vertebral fracture, also after adjusting for baseline vertebral fracture status and BMD. Thus, for a decrease of 9.3 pg/l in serum osteocalcin after 1 year's raloxifene therapy, the odds ratio (OR) for a new vertebral fracture during 3 years was 0.69 (0.54-0.88), p = 0.003. Similarly, for a decrease of 5.91 microg/l in serum bone alkaline phosphatase, OR was 0.75 (0.62-0.92), p = 0.005. The change in BMD over 12 and 24 months was not related to fracture risk in any of the analyses. The strongest predictor for vertebral fracture was prevalent vertebral fracture--even during therapy. The predictive value of baseline BMD was in the same order of magnitude as bone turnover change during raloxifene treatment. In conclusion, the change in bone turnover is related to fracture risk during raloxifene therapy. In contrast the change in BMD is not related to fracture risk. The strongest predictor for vertebral fracture is prevalent vertebral fracture.</abstract><cop>London</cop><pub>Springer</pub><pmid>11808544</pmid><doi>10.1007/s001980170020</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2001-11, Vol.12 (11), p.922-930 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_954612333 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Alkaline Phosphatase - metabolism Biological and medical sciences Biomarkers Bone Remodeling - drug effects Bone Remodeling - physiology Bones, joints and connective tissue. Antiinflammatory agents Chi-Square Distribution Collagen - metabolism Enzyme-Linked Immunosorbent Assay Estrogen Antagonists - therapeutic use Female Humans Logistic Models Medical sciences Multivariate Analysis Osteocalcin - metabolism Osteoporosis, Postmenopausal - complications Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - metabolism Pharmacology. Drug treatments Raloxifene Hydrochloride - therapeutic use Risk Factors Spinal Fractures - etiology Spinal Fractures - prevention & control |
| title | Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A16%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Six%20and%20twelve%20month%20changes%20in%20bone%20turnover%20are%20related%20to%20reduction%20in%20vertebral%20fracture%20risk%20during%203%20years%20of%20raloxifene%20treatment%20in%20postmenopausal%20osteoporosis&rft.jtitle=Osteoporosis%20international&rft.au=BJARNASON,%20N.%20H&rft.date=2001-11-01&rft.volume=12&rft.issue=11&rft.spage=922&rft.epage=930&rft.pages=922-930&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s001980170020&rft_dat=%3Cproquest_cross%3E18404856%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=848575865&rft_id=info:pmid/11808544&rfr_iscdi=true |